does anyone have information regarding who's on the Oncologic Drugs Advisory Committee (ODAC) and who will actually be voting on May 2nd?
i'd love to see a list of names and check out their CVs - after quite a bit of searching though i haven't found anything. i'm not with a firm or anything - just do this on my own for fun and i'm not sure if any institutional investors covering AVEO have this info and are willing to share.
i learned my lesson after DVAX and want to factor in any (non-disclosed) conflict(s) of interest that may affect the voting/decision making - it's a sad fact that it's not only about the data.
I beleive the roster will be posted the same time as the briefs, about 2 days prior to the meeting. The panels vary because they bring in experts for the indication in question.
The FDA brief though is vastly more important. Most practicing docs would want to approve as the drug will provide an option for many who can not tolerate the existing otpions. So unless the FDA presents something negative (either unknown data or their views on the OS issue) one would expect a thumbs up, regardless of the panel members.
There will be likely be one or two with a waived COI. This is almost certain as to gather leading experts you will have to get some who have been associated with other trials. This is nothing to get upset about.
Have you tried emailing the FDA and ask? I looked at a few of the recent panel votes as somebody here suggested and it had the names of the panelists. I think # of panelists varies depending on the panel. I read somewhere that there will be 13 or 14 panelists. ODAC recommended Inlyta on Dec, 2011 so I am sure panelists were named for that vote. Read Inlyta briefing doc yesterday and it was interesting.